Indications for: HYPERRAB

Postexposure prophylaxis of rabies (along with rabies vaccine).

Limitations of Use:

Only vaccinate persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer. For unvaccinated persons, the combination of HyperRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis. Beyond 7 days (after the first vaccine dose), HyperRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

Clinical Trials:

  • Two clinical trials evaluated HyperRAB in 20 healthy adults who received a single IM dose of 20 IU/kg HyperRAB or HyperRAB S/D. Rabies neutralizing antibody titers were monitored in serum for 21 days.

  • Both HyperRAB formulations achieved detectable titers of neutralizing antibodies to the rabies virus that persisted throughout the 21 day study period.

Adult Dosage:

See full labeling. Give by IM inj preferably at the time of 1st vaccine dose; may be given through 7th day after 1st vaccine dose is given. Not previously vaccinated: 20 IU/kg (0.0665mL/kg) once. If feasible, up to full dose should be infiltrated in area around wound and the rest (if any) into deltoid muscle of upper arm or lateral thigh muscle.

Children Dosage:

Not established.

HYPERRAB Warnings/Precautions:

Previously immunized with rabies vaccine with a confirmed adequate rabies antibody titer: not recommended. Contains human plasma; monitor for possible infection transmission. IgA-deficiency. Prior history of allergic reactions to human immunoglobulins. Have epinephrine inj available. Pregnancy. Nursing mothers.

HYPERRAB Classification:

Immune globulin.

HYPERRAB Interactions:

Do not administer repeated doses after administration of rabies vaccine; may suppress immune response to the vaccine. Avoid live vaccines for 4 months (eg, measles, mumps, polio, rubella).

Adverse Reactions:

Inj site pain or nodule, headache, abdominal pain, diarrhea, flatulence, nasal congestion, oropharyngeal pain; hypersensitivity reactions.

Generic Drug Availability:


How Supplied:

Single-dose vial (1mL, 3mL, 5mL)—1